National Bank of Canada
CRL icon

National Bank of Canada’s Charles River Laboratories CRL Stock Holding History

National Bank of Canada’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.29M Buy
18,935
+1,001
+6% +$178K ﹤0.01% 952
2026
Q1 		$3.09M Sell
17,934
-9,212
-34% -$1.71M ﹤0.01% 979
2025
Q4 		$5.42M Sell
27,146
-919,623
-97% -$167M ﹤0.01% 859
2025
Q3 		$148M Buy
946,769
+511,901
+118% +$81.3M 0.15% 126
2025
Q2 		$66M Buy
434,868
+400,881
+1,180% +$53.5M 0.06% 248
2025
Q1 		$5.12M Buy
33,987
+10,132
+42% +$1.7M 0.01% 891
2024
Q4 		$4.4M Buy
23,855
+2,639
+12% +$508K ﹤0.01% 1004
2024
Q3 		$4.18M Buy
21,216
+6,627
+45% +$1.38M ﹤0.01% 875
2024
Q2 		$2.96M Sell
14,589
-28,089
-66% -$6.36M ﹤0.01% 863
2024
Q1 		$9.74M Sell
42,678
-61,096
-59% -$14.6M 0.01% 621
2023
Q4 		$23.4M Sell
103,774
-18,681
-15% -$3.67M 0.04% 365
2023
Q3 		$23.5M Buy
122,455
+41,662
+52% +$8.55M 0.04% 379
2023
Q2 		$16.9M Sell
80,793
-7,859
-9% -$1.56M 0.03% 405
2023
Q1 		$17.8M Sell
88,652
-13,711
-13% -$3.11M 0.04% 300
2022
Q4 		$22.3M Buy
102,363
+51,321
+101% +$11.2M 0.06% 264
2022
Q3 		$10.4M Buy
51,042
+3,070
+6% +$663K 0.06% 357
2022
Q2 		$10.5M Buy
47,972
+1,487
+3% +$363K 0.05% 379
2022
Q1 		$13.8M Buy
46,485
+44,519
+2,264% +$13.7M 0.04% 384
2021
Q4 		$688K Buy
+1,966
New +$764K ﹤0.01% 1162

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

National Bank of Canada's CRL Position: Q2 2026 in Review

National Bank of Canada increased its Charles River Laboratories (CRL) stake by 5.6% in Q2 2026, buying an estimated $178K and bringing the position to 18,935 shares worth $4.29M. The position accounts for ﹤0.01% of the portfolio, ranked #952.

National Bank of Canada first reported a position in CRL in Q4 2021 and has held it in 19 quarters since. The position peaked at $148M in Q3 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • National Bank of Canada held 18,935 shares of Charles River Laboratories worth $4.29M as of Q2 2026.
  • National Bank of Canada bought 1,001 Charles River Laboratories shares in Q2 2026, an estimated $178K.
  • Charles River Laboratories made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #952 holding.
  • National Bank of Canada first reported a position in Charles River Laboratories in Q4 2021 and has held it in 19 quarters since.
  • National Bank of Canada's Charles River Laboratories position peaked at $148M in Q3 2025.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.